CASRAI Dictionary

Tag: Lambert Toolkit

  • Research Contract Template UK: 4 Types Compared

    A UK research contract template is a pre-negotiated model agreement — MTA, mCTA, MNCA or a Lambert/Brunswick collaboration agreement — chosen by the nature of the relationship between the parties, not by habit. Sending samples calls for a material transfer agreement; an NHS-regulated commercial trial calls for a model Clinical Trial Agreement; charity- or government-funded research uses the MNCA; and multi-party R&D with shared IP uses a Lambert or Brunswick collaboration agreement. Picking the wrong one causes avoidable delay, as UK funders and the NHS expect the correct template used unmodified.

    A research contract template UK researchers reach for is not one generic document but one of four distinct families, each governed by a different body with different rules on amendment. This article maps each template to the relationship it was built for.

    What counts as a UK research contract template?

    A UK research contract template is a standardised legal agreement, published and maintained by a national body (the Health Research Authority, UKRI, or the Association of Research Managers and Administrators), for a specific category of research relationship. The HRA states plainly: “there are several different model agreements, and you should use the one that is most appropriate for your study type and sponsorship arrangements.” Under the National Directive on Commercial Contract Research, HRA and Health and Care Research Wales (HCRW) Approval is typically issued conditionally on using the unmodified template — a waiver is possible only in exceptional circumstances.

    • Material Transfer Agreement (MTA) — for transferring biological or physical materials only
    • Model Clinical Trial Agreement (mCTA) family — for NHS-regulated commercial and non-interventional studies
    • Model Non-Commercial Agreement (MNCA) — for publicly or charity-funded research with no commercial sponsor
    • Collaboration agreement (Lambert Toolkit or Brunswick Templates) — for multi-party R&D where intellectual property is shared

    Material Transfer Agreements (MTA): moving materials, not money

    An MTA governs the transfer of physical or biological materials — tissue, cell lines, reagents, data-carrying media — between organisations, without itself constituting a clinical trial or a funded collaboration. Where an NHS or Health and Social Care (HSC) organisation is involved, the model Material Transfer Agreement published by the HRA is the required unmodified template. Where the transfer is purely between two universities or not-for-profit bodies, the Brunswick Material Transfer Agreement, hosted free by the Association of Research Managers and Administrators (ARMA), is the standard route.

    Use an MTA — not a collaboration agreement — whenever the relationship is a one-directional or reciprocal transfer of materials with no joint research programme, no shared funding, and no clinical intervention attached.

    Clinical Trial Agreements (mCTA): the NHS-regulated route

    An mCTA is the mandatory unmodified contract for a commercial sponsor running a regulated clinical trial at an NHS or HSC site. The family also includes the mCIA (medical devices), ATMP-mCTA (advanced therapy medicinal products), PC-mCTA (primary care) and mNISA (non-interventional commercial studies) — each scoped to a specific trial type.

    An updated suite of UK model agreements came into use on 28 April 2026, reflecting changes to the Clinical Trials Regulations that took effect the same day, per HRA and the Clinical Trials Toolkit. New IRAS submissions are expected to use the current versions.

    Template Used when Host / steward Modifiable?
    MTA (HRA) Transferring materials to/from an NHS/HSC organisation Health Research Authority No — unmodified use expected
    Brunswick MTA Transferring materials between universities/not-for-profits ARMA No — off-the-shelf template
    mCTA / mCIA / ATMP-mCTA / PC-mCTA / mNISA Commercial or non-interventional trials at NHS/HSC sites HRA + NIHR No — mandated under the National Directive on Commercial Contract Research
    MNCA Non-commercial, publicly/charity-funded research at NHS/HSC sites HRA No — policy expectation of unmodified use
    Lambert Toolkit collaboration agreements University-business R&D with shared IP GOV.UK / UKRI-endorsed Yes — a decision guide selects from several IP models
    Brunswick collaboration agreements University-university or not-for-profit R&D ARMA Limited — designed for use largely as published

    MNCA: the template for non-commercial research

    The Model Non-Commercial Agreement (MNCA) is the UK-wide template for research at NHS or HSC organisations that is funded by government, charity or academic sources rather than a commercial sponsor. Unlike commercial contract research, there is no equivalent National Directive mandating its use, but the HRA maintains a clear “policy expectation that the appropriate UK template will be used without modification,” and warns that departing from this “may result in prolonged central and participating NHS organisation review.” Administrators searching for an “mnca template” should treat it as the non-commercial counterpart to the mCTA family, not a lighter-touch version of a collaboration agreement.

    Collaboration agreements: Lambert Toolkit vs Brunswick Templates

    Collaboration agreements apply where two or more organisations jointly conduct research and need to allocate intellectual property, publication rights and liability — a fundamentally different problem from moving materials or running a regulated trial. The Lambert Toolkit, published on GOV.UK and endorsed by UK Research and Innovation (UKRI), is built for university-business collaborations: it offers a decision guide plus seven model agreements for one-to-one projects and four consortium agreements for multi-party collaborations, each reflecting a different approach to IP ownership and exploitation.

    Where both parties are universities or similar not-for-profit organisations, the Brunswick Suite of Templates, hosted by ARMA, provides an equivalent academic research collaboration agreement designed to avoid renegotiating IP terms from scratch on every project.

    • Choose the Lambert Toolkit when a business is a party and IP exploitation terms need active negotiation
    • Choose Brunswick Templates when all parties are universities or not-for-profit research organisations

    Choosing the right template by relationship type

    The decision is governed by relationship type, not by project size or funding value. Ask three questions in sequence: is anything commercial being run as a clinical trial at an NHS/HSC site (mCTA family); if not, is material simply moving between organisations with no joint programme (MTA); if not, is the research funded non-commercially at an NHS/HSC site (MNCA); and only if none of those apply — a multi-party research collaboration with shared IP — does a Lambert or Brunswick collaboration agreement apply.

    Frequently asked questions

    What is a model Clinical Trial Agreement (mCTA)?

    An mCTA is the HRA-published, NIHR-supported unmodified contract required for commercial, industry-sponsored clinical trials run at NHS or HSC organisations, mandated by the National Directive on Commercial Contract Research alongside sibling templates for devices, ATMPs and primary care.

    What is the difference between an MTA and a collaboration agreement?

    An MTA covers only the transfer of physical or biological materials between two parties with no joint research programme. A collaboration agreement — Lambert Toolkit or Brunswick — governs a shared research programme with joint intellectual property, publication rights and liability, making it a materially broader and more negotiated document.

    What is an MNCA and when is it used?

    The MNCA (Model Non-Commercial Agreement) is the UK template used when non-commercially funded research — government, charity or academic — takes place at an NHS or HSC organisation. It mirrors the mCTA’s unmodified-use expectation but applies where no commercial sponsor is involved.

    Can I modify a UK model agreement instead of using it unmodified?

    Only with a granted waiver, which the HRA warns “is liable to add many months of central negotiation” and “is unlikely to be agreed.” Any proposed modification must be disclosed in the IRAS cover letter with a tracked-change version and a change-by-change rationale.

    Implications and what to check next

    The practical takeaway is procedural discipline: identify the relationship first, select the corresponding UK template second, and reserve bespoke drafting for the rare case where no UK template exists — a justification that must itself be stated clearly in the IRAS application, since HRA guidance notes this “may expedite the review.” Following the 28 April 2026 regulatory changes, administrators should check the HRA’s model agreements page and the Clinical Trials Toolkit before assuming a previously downloaded template is still current. Institutions building internal contracting guidance should map each incoming request against these four relationship types before a bespoke agreement is drafted — this discipline is what keeps study set-up close to the pre-cleared norm rather than the multi-month waiver-negotiation outlier.

  • Material Transfer Agreement: A UK & US Guide for Research Administrators

    A material transfer agreement is the legal contract that must be signed before tangible research materials — cell lines, reagents, biological samples, software, or datasets — move between two organisations. It fixes who owns the material and any derivatives, sets what the recipient may do with it, and allocates liability. A material transfer agreement (MTA) is required whenever proprietary or regulated research material crosses an institutional boundary, whether between two universities, from academia to industry, or the reverse.

    Definition: a material transfer agreement is a contract that governs the transfer of tangible research materials between two organisations when the recipient intends to use the material for their own research purposes.

    Jump to:

    What is a material transfer agreement?

    A material transfer agreement sits between two parties: a provider, who supplies the material, and a recipient, who receives it for research, testing, or evaluation. Almost no research organisation will release physical material — a plasmid, an antibody, a chemical compound, a mouse line, patient-derived tissue, or bundled software and data — without one in place.

    Three types of MTA are most common at academic institutions: transfers between academic or research institutions, transfers from academia to industry, and transfers from industry to academia. Each carries different negotiating priorities, since a commercial provider will typically restrict use and reserve rights over derivatives more tightly than a non-profit research institute would.

    When is a material transfer agreement required?

    An MTA is required whenever material is not already covered by a broader collaboration agreement, consortium agreement, or funding contract that addresses ownership and use of transferred materials. It becomes mandatory, rather than merely advisable, in three recurring situations.

    • Human tissue transfers: in the UK, transfer of human tissue or cells for research is governed by the Human Tissue Act 2006, and an MTA (or equivalent material transfer form) is needed to evidence lawful, consented use and to satisfy Human Tissue Authority licensing conditions.
    • Materials with commercial or patent potential: where the material, or a discovery derived from it, could be patented, an MTA is used to fix inventorship, licensing, and revenue-sharing terms before any transfer takes place.
    • Cross-institutional research collaborations: whenever a researcher sends or receives compounds, cell lines, reagents, or proprietary datasets from an external organisation without an overarching agreement already in force.

    Institutional practice is consistent on one point: individual principal investigators cannot sign MTAs on behalf of their university. UK universities route requests through a research contracts or Research and Innovation Services (RIS) office; US institutions route them through a Technology Transfer Office (TTO). This centralisation protects the institution’s intellectual property position and ensures the agreement is enforceable.

    What clauses does a standard MTA contain?

    Most MTAs, regardless of jurisdiction, follow a recognisable clause structure. Understanding this structure is the fastest way for a research administrator to review a third-party MTA against institutional norms rather than starting from a blank page.

    • Permitted use: restricts the material to a defined research purpose, typically excluding commercial use, further distribution, or use in human subjects without separate approval.
    • Ownership and derivatives: confirms the provider retains ownership of the original material, and defines who owns modifications, progeny, and unmodified derivatives.
    • Intellectual property and inventions: allocates rights over any patentable invention arising from use of the material, often with a first option to license back to the provider.
    • Publication rights: preserves the recipient’s right to publish results, sometimes subject to a short pre-publication review period for the provider to flag confidential information.
    • Confidentiality: protects any proprietary information disclosed alongside the material.
    • Warranties, indemnities and liability: the provider typically disclaims warranties on the material’s fitness for purpose and safety, while the recipient indemnifies the provider against misuse.
    • Term, termination and disposition: specifies how long the agreement runs, and whether unused material must be returned or destroyed at the end of the project.

    These clauses collectively protect the parties’ research and commercial interests in the material while ensuring compliance with applicable regulatory requirements, from data protection through to biosafety.

    How does UK practice differ from US practice?

    The underlying clause structure is similar on both sides of the Atlantic, but the institutional machinery around MTAs differs in three practical respects: which model agreement negotiators start from, which office holds signing authority, and which professional body supports that office.

    Aspect UK practice US practice
    Model agreement Lambert Toolkit model materials transfer agreements, published by the UK Intellectual Property Office Uniform Biological Material Transfer Agreement (UBMTA), developed by the National Institutes of Health (NIH)
    Signing authority University Research and Innovation Services / research contracts team Institutional Technology Transfer Office (TTO)
    Human tissue regulation Human Tissue Act 2006, overseen by the Human Tissue Authority Institutional Review Board (IRB) oversight under the federal Common Rule
    Professional body ARMA (Association of Research Managers and Administrators) NCURA (National Council of University Research Administrators) and AUTM
    Template repository ARMA’s published MTA templates, including a non-human tissue MTA AUTM’s MTA toolkit and public list of UBMTA signatory institutions

    The UBMTA is a master agreement: once a US institution signs it, subsequent transfers between fellow signatories only require a short implementing letter rather than a fresh negotiation, which is why AUTM’s signatory list matters operationally. The UK has no single equivalent master agreement; Lambert Toolkit models function as drafting templates rather than a pre-signed master framework, so each UK MTA is typically negotiated afresh, even between repeat institutional partners. ARMA, NCURA, and their European counterpart EARMA are all national associations affiliated to INORMS, the International Network of Research Management Societies, reflecting how widely MTA negotiation sits within the research administration profession globally.

    Material transfer agreement FAQs

    What is a material transfer agreement?

    A material transfer agreement is a contract that governs the transfer of tangible research materials — such as reagents, cell lines, plasmids, vectors, chemical compounds, or software — between two organisations when the recipient intends to use the material for its own research purposes.

    What is the difference between MTA and NDA?

    An MTA governs the physical transfer of tangible material and covers ownership, permitted use, and derivatives, while a non-disclosure agreement (NDA) governs only the confidentiality of shared information. Many MTAs incorporate confidentiality terms directly, making a separate NDA unnecessary for that transfer.

    What is the standard material transfer agreement?

    There is no single global standard MTA. The closest equivalent is the US Uniform Biological Material Transfer Agreement (UBMTA), a pre-agreed master framework maintained by AUTM. UK institutions instead draft from Lambert Toolkit model clauses or their own institutional precedent, negotiating each transfer individually.

    What is the purpose of an MTA?

    An MTA’s purpose is to regulate the use and distribution of transferred material, define legal provisions such as warranties, indemnities and risk allocation, specify each party’s access to results, and settle ownership of any resulting intellectual property and publication rights.

    What this means for research offices

    Material transfer volumes are rising as biological data-sharing mandates and open-research policies push more labs to exchange materials alongside associated datasets. As funders increasingly expect materials and data underlying published results to be shareable, research offices should expect MTA review queues — and negotiation over restrictive provider terms — to keep growing rather than shrink. Building clause-level familiarity now, rather than treating every incoming MTA as a bespoke legal puzzle, is the most efficient way for a research administration office to keep transfers moving without exposing the institution to unmanaged IP or liability risk.